Mereo BioPharma Group plc SEC filings MREO
Mereo BioPharma Group plc has 439 filings in SEC EDGAR's recent list, going back to Dec 1, 2017. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 19, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 4, 2024 | — |
| CORRESP | Letter to the SEC | Dec 3, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 2, 2024 | — |
| EFFECT | Filing | May 22, 2024 | — |
| CORRESP | Letter to the SEC | May 21, 2024 | — |
| UPLOAD | Letter from the SEC | May 20, 2024 | — |
| 8-A12B/A | Filing | Dec 18, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 24, 2022 | — |
| CORRESP | Letter to the SEC | Aug 19, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2022 | — |
| CT ORDER | Filing | Jun 13, 2022 | — |
| 8-A12B/A | Filing | May 17, 2022 | — |
| EFFECT | Filing | Sep 30, 2021 | — |
| CORRESP | Letter to the SEC | Sep 29, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2021 | — |
| CORRESP | Letter to the SEC | Sep 7, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2021 | — |
| EFFECT | Filing | Oct 21, 2020 | — |
| CORRESP | Letter to the SEC | Oct 20, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 9, 2020 | — |
| EFFECT | Filing | Jul 10, 2020 | — |
| EFFECT | Filing | Jul 9, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2020 | — |
| CORRESP | Letter to the SEC | Jul 9, 2020 | — |
| D | Filing | Jun 12, 2020 | — |
| EFFECT | Filing | Mar 19, 2020 | — |
| CORRESP | Letter to the SEC | Mar 18, 2020 | — |
| CORRESP | Letter to the SEC | Mar 6, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 2, 2020 | — |
| CERT | Filing | Apr 24, 2019 | — |
| 8-A12B/A | Form 8-a12b/a | Apr 15, 2019 | — |
| CT ORDER | Filing | Mar 21, 2019 | — |
| EFFECT | Filing | Mar 20, 2019 | — |
| EFFECT | Filing | Mar 20, 2019 | — |
| 425 | Form 425 | Mar 15, 2019 | — |
| 425 | Form 425 | Mar 12, 2019 | — |
| 425 | Form 425 | Feb 22, 2019 | — |
| RW | Form rw | Feb 21, 2019 | — |
| 425 | Form 425 | Feb 15, 2019 | — |
| 425 | Form 425 | Feb 12, 2019 | — |
| 425 | Form 425 | Jan 7, 2019 | — |
| 425 | Form 425 | Dec 11, 2018 | — |
| 425 | Form 425 | Dec 6, 2018 | — |
| 425 | Form 425 | Dec 6, 2018 | — |
| 425 | Form 425 | Dec 6, 2018 | — |
| 425 | Form 425 | Dec 6, 2018 | — |
| CERT | Filing | Apr 18, 2018 | — |
| 8-A12B | Filing | Apr 9, 2018 | — |
| DRS/A | Filing | Mar 14, 2018 | — |
| DRS/A | Filing | Feb 27, 2018 | — |
| DRS/A | Filing | Jan 18, 2018 | — |
| DRS | Filing | Dec 1, 2017 | — |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MREO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1719714
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.